Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Why Amgen Stock Wilted on Wednesday
05:06pm, Wednesday, 01'st Feb 2023
The company's latest quarter wasn't its most impressive.
Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints
12:02pm, Wednesday, 01'st Feb 2023
Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
06:01am, Wednesday, 01'st Feb 2023
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare
Amgen Inc. (AMGN) Q4 2022 Earnings Call Transcript
11:39pm, Tuesday, 31'st Jan 2023
Amgen Inc. (NASDAQ:AMGN ) Q4 2022 Earnings Conference Call January 31, 2023 4:30 PM ET Company Participants Arvind Sood - Vice President of Investor Relations Bob Bradway - Chairman & Chief Executive
AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST
11:34pm, Tuesday, 31'st Jan 2023
THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast f
Amgen (AMGN) Surpasses Q4 Earnings and Revenue Estimates
06:32pm, Tuesday, 31'st Jan 2023
Amgen (AMGN) delivered earnings and revenue surprises of 1.24% and 1.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Barron's And Bloomberg 2023 Ideal Dividend Stocks Of The Year
05:13pm, Tuesday, 31'st Jan 2023
Two Barron's Annual Roundtable, plus one Bloomberg Intelligence articles published late-January listed 99 intriguing stocks for 2023; 77 were unduplicated US publicly-listed companies, of which, 56 pa
Amgen's Q4 tops views, but 2023 guidance falls on lower end of expectations
04:44pm, Tuesday, 31'st Jan 2023
Amgen Inc. topped Wall Street expectations for its fourth quarter, but the drug maker's shares fell after hours as its 2023 guidance fell on the lower end of Wall Street's expectations.
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
12:12pm, Tuesday, 31'st Jan 2023
AbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar copy. But AbbVie stock was mostly unmoved.
Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts
02:34pm, Monday, 30'th Jan 2023
Biopharmaceutical company Amgen (NASDAQ: AMGN ) announced this morning it has laid off about 300 U.S. employees, equivalent to roughly 1.2% of its workforce. The company cited recent organizational ch
Is a Surprise Coming for Amgen (AMGN) This Earnings Season?
09:47am, Monday, 30'th Jan 2023
Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors
03:53pm, Tuesday, 24'th Jan 2023
The start of the year is a good time to add to your existing portfolio or start new positions. An excellent source to look for ideas is among the Dogs of the Dow.
2 Top Passive-Income Stocks to Own in 2023
07:05pm, Sunday, 22'nd Jan 2023
These dividend stocks can deliver both downside protection and capital appreciation.
3 Dividend Stocks You Can Safely Hold for Years
09:00am, Saturday, 21'st Jan 2023
Look for the top companies in businesses the world perpetually needs.
Nicholas Ward's Dividend Growth Portfolio: December/Full Year 2022 Review
04:46pm, Wednesday, 18'th Jan 2023
My passive income was up by 46.50% on a year-over-year basis during December. For the full-year in 2022, my passive income rose by 23.73%.
